![]() | |
Clinical data | |
---|---|
Trade names | Voxzogo |
Other names | BMN-111 |
License data |
|
Pregnancy category | |
Routes of administration | Subcutaneous injection |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
CAS Number | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C176H290N56O51S3 |
Molar mass | 4102.78 g·mol−1 |
3D model (JSmol) | |
| |
|
Vosoritide, sold under the brand name Voxzogo, is a medication used for the treatment of achondroplasia,[3][4][5] a genetic condition that causes severely short stature and disproportionate growth.[4]
Achondroplasia is caused by a genetic mutation that increases the activity of a certain growth regulation gene called fibroblast growth factor receptor 3 (FGFR3). The overabundance of protein coded by the FGFR3 gene prevents normal bone growth.[4] Vosoritide works by binding to a specific receptor called natriuretic peptide receptor B that reduces the growth regulation gene's activity, thus allowing for bone growth.[4]
The most common side effects include injection site reactions (such as swelling, redness, itching, or pain), vomiting, and decreased blood pressure.[3][4][5]
Vosoritide was approved for medical use in the European Union in August 2021,[5][6][7] and in the United States in November 2021.[4][8] The US Food and Drug Administration considers it to be a first-in-class medication.[9]
Voxzogo EPAR
was invoked but never defined (see the help page).© MMXXIII Rich X Search. We shall prevail. All rights reserved. Rich X Search